News › Infrastructure  ·  14 May 2026, 10:03 AM IST  ·  4 months ago

Mixed Cues: Advani Recommends Infra, Pharma, Exporters Amidst FII

VolatileBias: Bullish +5190% confidenceInfrastructurePharmaceuticals

In one line — Consider long positions in fundamentally strong pharma companies with robust pipelines and good regulatory standing.

Bearish
Bullish
−1000+51+100

Source: Economic Times · AI-summarised by Anadi · Updated 14 May 2026, 10:27 AM IST

Infrastructurewatching
Pharmaceuticalswatching
Export Oriented Industrieswatching

What Happened

Pashupati Advani of Global Foray has advised Indian investors to navigate current market turbulence, characterized by inflation and foreign investor sell-offs, by focusing on fundamental strength. He specifically pointed towards opportunities in infrastructure, export-oriented companies, and the pharmaceutical sector.

Why It Matters (for you)

This advice is crucial for Indian traders as it provides a strategic direction during a period of high volatility and FII outflows, which have significantly impacted broader market sentiment. Identifying resilient sectors and fundamental plays can help mitigate risks and uncover potential alpha in a challenging environment.

Impact on Indian Markets

The advice is positive for companies in the infrastructure sector, which are likely to benefit from government spending. Export-oriented companies could see positive sentiment due to potential currency advantages or global demand. The pharmaceutical sector, including major players like SUNPHARMA, DRL, and CIPLA, is also highlighted as a defensive and growth-oriented opportunity.

What Traders Should Watch Next

Traders should monitor government announcements regarding infrastructure projects and spending. Keep an eye on FII flow data for signs of stabilization or reversal. For pharma, watch for regulatory updates, new product launches, and quarterly earnings to confirm sector strength and individual stock performance.

Key Evidence

  • Indian markets face ongoing turbulence with imminent slowdown due to inflation and supply chain issues.
  • Foreign investors are selling off, impacting the broader market.
  • Pashupati Advani advises caution and highlights opportunities in infrastructure, exporters, and pharma.
  • Investors should prioritize fundamentals and government spending priorities.
  • Risk flag: USFDA/regulatory hurdles for specific drugs or manufacturing facilities